MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage ...
MSD's confidence in its anti-TL1A antibody tulisokibart in inflammatory diseases has been made apparent by a decision to start trials of the drug in three more indications. Already in phase 3 testing ...
Thousands of items for kids from hundreds of families around the metro area are up for grabs at a super sale.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback